Skip to main navigation Skip to search Skip to main content

Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study

  • Tien Hsing Chen
  • , Te Hsiung Wang
  • , Ming Lung Tsai
  • , Ming Shyan Lin
  • , Tzu Hsien Tsai
  • , Tien Shin Chou
  • , Chin Ju Tseng
  • , Jhih Wei Dai
  • , Chien Wei Cheng
  • , Ning I. Yang
  • , Ming Jui Hung
  • , Yuan Lin*
  • *Corresponding author for this work
  • Tazuke Kofukai, Medical Research Institute, Kitano Hospital
  • Kyoto University
  • New Taipei Municipal Tucheng Hospital
  • Chang Gung University
  • Chang Gung Memorial Hospital
  • Chia-Yi Christian Hospital

Research output: Contribution to journal › Journal Article › peer-review

6 Scopus citations

Abstract

Aims: Limited evidence exists regarding the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in cardiovascular and renal outcomes in patients with advanced chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m2. Methods: We enrolled patients with type 2 diabetes mellitus and eGFR < 30 mL/min per 1.73 m2 who were prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) from 2016 to 2022 (n = 117,924). The primary cardiovascular outcomes included cardiovascular death, myocardial infarction, ischemic stroke, and heart failure-related admission. Renal outcomes encompassed an eGFR decline of >50 %, a doubling of serum creatinine levels, and progression to dialysis. Results: The study included 6,730 participants [SGLT2i, n = 1,086; DPP4i, n = 5,644]. In both groups, the composite cardiovascular events developed at a rate of 13.2 events per 100 person-years (PYs) [hazard ratio (HR), 0.92; 95 % confidence interval (CI) 0.71–1.19]. The composite of renal events occurred at a rate of 18.5 and 16.2 events per 100 PYs in the SGLT2i and DPP4i groups, respectively [subdistribution HR 1.12; 95 % CI 0.91–1.38]. Conclusions: Compared to DPP4i, SGLT2i did not show superiority in the reduction of cardiovascular or renal events in CKD stage 4–5 patients.

Original languageEnglish
Article number112205
JournalDiabetes Research and Clinical Practice
Volume224
DOIs
StatePublished - 06 2025

Bibliographical note

Publisher Copyright:
© 2025 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cardiovascular outcome
  • Diabetic kidney disease
  • Dipeptidyl peptidase 4 inhibitor
  • Renal outcome
  • Sodium-glucose cotransporter 2 inhibitor

Fingerprint

Dive into the research topics of 'Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study'. Together they form a unique fingerprint.

Cite this